Breast-Specific Gamma Imaging (BSGI), Molecular Breast Imaging (MBI), or scintimammography with breast-specific gamma camera

BlueCross BlueShield Association

Record Status
This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database.

Citation
BlueCross BlueShield Association. Breast-Specific Gamma Imaging (BSGI), Molecular Breast Imaging (MBI), or scintimammography with breast-specific gamma camera. Chicago: BlueCross BlueShield Association (BCBS). TEC Assessment 28(2). 2013

Authors' objectives
To ascertain the accuracy (sensitivity, specificity, positive predictive value, and negative predictive value) of breast-specific gamma imaging, molecular breast imaging, or scintimammography using a breast-specific gamma camera (referred to as BSGI/MBI hereafter) compared to alternative imaging modalities such as MRI, ultrasound (US), and mammography, when used in women undergoing breast cancer screening, including those with dense breasts or at high risk of breast cancer, or in women with suspicious physical or imaging findings.

Project page URL

Final publication URL

PubMedID
23865107

Indexing Status
Subject indexing assigned by NLM

MeSH
Blue Cross Blue Shield Insurance Plans; Breast Neoplasms /diagnosis /economics /radiography /radionuclide imaging; Drug Approval; Female; Gamma Camera; Mammography /methods; Molecular Imaging /methods; Radiation Dosage; Radionuclide Imaging /economics /instrumentation /methods; Radiopharmaceuticals; Sensitivity and Specificity; Technetium Tc 99m Sestamibi; Technology Assessment, Biomedical; United States; United States Food and Drug Administration

Language Published
English

Country of organisation
United States

English summary
An English language summary is available.

Address for correspondence
BlueCross BlueShield Association, Technology Evaluation Center, 225 North Michigan Ave, Chicago, Illinois, USA.
Tel: 888 832 4321 Email: tec@bcbsa.com